Dresden, July 5, 2024 - DEMECAN is pleased to announce that it has become the first German company to receive a cultivation license for medical cannabis under the new Medical Cannabis Law (MedCanG). This license includes several different phenotypes that DEMECAN will now cultivate for the German market. With this license, DEMECAN can immediately double its production and fully utilize the existing production capacities at the "Cannabis Campus" in Ebersbach. This license allows DEMECAN to achieve an annual yield of approximately 2 tons, with no quantity limit specified.

This license is crucial to meet the growing demand for medical cannabis and marks a
turning point in supply by shifting the focus from imports to more domestic production.

Dr. Adrian Fischer, physician and Managing Director responsible for cultivation,
commented: "This license is a huge step forward for DEMECAN and the entire
industry. We are proud to be the first German company to take this step and look
forward to providing our high-quality cannabis strains soon. Our goal is to further
increase production and thus improve supply security, as there are currently many
shortages in patient care."

The company is also pleased to announce that it achieved strong revenue growth since
April 2024. Dr. Philipp Goebel, Managing Director and responsible for sales, adds:
"The significantly increased demand is reflected in our strong sales and shows that we
are on the right track. The new cultivation permit not only allows us to meet the growing
demand but also enables the sustainable development of our company."

Since its founding in 2017, DEMECAN has established itself as a pioneer in the
German cannabis scene. As the only independent company in Germany covering the
entire value chain for medical cannabis - from cultivation and processing to storage
and delivery to pharmacies - DEMECAN has made a significant contribution to
ensuring patients are supplied with high-quality cannabis products.

The legalization of cannabis on April 1, 2024, has also significantly boosted the market
for medical cannabis, and DEMECAN's new cultivation license sends another positive
signal for the industry. With the expansion of production in Germany, DEMECAN aims
to offer consumers quality-tested products from strictly regulated production.

About DEMECAN

DEMECAN is an independent German company covering the entire value chain of
medical cannabis - from cultivation and pharmaceutical manufacturing to delivery to
pharmacies. The company was founded with the goal of providing patients with highquality access to medical cannabis "Made in Germany."

As the only independent German company, DEMECAN received the contract from the
Federal Institute for Drugs and Medical Devices (BfArM) in May 2019 to grow medical
cannabis in Germany. Cultivation and further processing are carried out according to
the highest pharmaceutical standards at the facility near Dresden. Additionally,
DEMECAN imports medical cannabis from producers worldwide to expand its range
and meet high-quality standards. The company also offers laboratory and processing
services related to medical cannabis.

DEMECAN is a member of the Federal Association of Pharmaceutical Cannabinoid
Companies (BPC) and the Federal Association of the Cannabis Industry (BvCW). With
its commitment to the highest quality and safety in medical cannabis production,
DEMECAN contributes to improving patient care in Germany and Europe.

For more information: www.demecan.de

Press Contact: Franz Großmann
Mail: press@demecan.de
Mobil: +49 151 742 25 332

Berlin/Ebersbach, 07. August 2024 - DEMECAN, Germany's premier medical
cannabis producer, is pleased to announce the successful completion of its latest
funding round, marking a significant step forward in its growth strategy. This influx of
capital will enhance pharmacy distribution capabilities through innovative SaaS
solutions and the Company’s online pharmacy platform www.herbery.de. Furthermore,
investments will be made into internationalization and product innovation.

Jörg Sellmann, Managing Director and responsible for finance, adds: "This financing
round is a significant milestone for DEMECAN. It gives us the necessary resources to
accelerate our growth trajectory and capitalize on the burgeoning opportunities within
the medical cannabis sector, especially following its reclassification in April. Demecan
has the best basis for this, as positive results have already been achieved since April
and will improve further due to the full utilization of production capacities in
accordance with the new cannabis law in Germany "

The round, led by Florida-based Trog Hawley Capital, with additional participation from
new and existing investors, represents the first institutional investment from a U.S.
based investor in DEMECAN. Trog Hawley Capital provides capital and strategic
advice to exceptional entrepreneurs and management teams, leveraging over 10 years
of experience building and investing in U.S. multi-state cannabis operators. The
participation of international investors with such experience underscores DEMECAN’s
strength as the market leader, as well as the potential of the German market for
medical cannabis.

"We are pleased with the support of our investors, and their trust in our good work,"
says Dr. Constantin von der Groeben, co-founder and Managing Director of
DEMECAN. "The participation of new investors from the USA shows that our approach
and vision are recognized internationally."

Adam Ryan, CEO of Trog Hawley, adds: " Europe's cannabis market, particularly
Germany, presents exceptional growth prospects far exceeding those in more mature
markets. DEMECAN's comprehensive infrastructure, including its production facilities
and Cannabis Campus with advanced laboratory and processing capabilities, positions
it as a frontrunner in the industry. We are very excited to be part of the team and look
forward to supporting their next growth phase."

About DEMECAN

DEMECAN is an independent German company that covers the entire value chain of
medical cannabis - from cultivation through pharmaceutical production to delivery to
pharmacies. The company was founded in 2017 and has since established itself as a
pioneer in the German cannabis market. With its commitment to the highest quality and safety in medical cannabis production, DEMECAN contributes to improving patient care in Germany and Europe.

In May 2019, DEMECAN received the contract to grow medical cannabis in Germany from the Federal Institute for Drugs and Medical Devices (BfArM). Cultivation and processing are carried out according to the highest pharmaceutical standards at the facility near Dresden. In July 2024, DEMECAN also received a cultivation license under the new Medical Cannabis Act. In addition, DEMECAN imports medical cannabis from producers worldwide to expand its range and meet high-quality standards. The company also offers laboratory and processing services related to medical cannabis and provides pharmacies with a logistics solution for handling medical cannabis.

DEMECAN is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and the Federal Association of the Cannabis Industry (BvCW).

About Trog Hawley Capital

Founded in 2012 and based in West Palm Beach, Florida, Trog Hawley Capital leverages a team of serial entrepreneurs, seasoned operators, and investment professionals who collectively have founded and grown businesses worth over $1 billion. Trog Hawley Capital founded, and operated Tryke Companies, a multi-state cannabis operator, for nearly a decade, eventually exiting the business via sale to a strategic acquirer in late-2022. The firm has carved its niche in direct venture investing with 30+ portfolio companies across verticals such as big data, cyber security, cannabis, e-commerce, energy infrastructure, enterprise, fintech, gaming/esports, and healthtech.

For more information: www.demecan.de

Press contact: Franz Großmann
Email: press@demecan.de
Mobile: +49 151 742 25 332